EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
22 MARCH 2013
Speaking in advance of World Tuberculosis (TB) day (24 March), Dr Roberto Frontini, President of the European Association of Hospital Pharmacists (EAHP), has warned European healthcare system managers and policy makers to take proactive measures now to meet the growing problem of Multi-Drug Resistant TB and the emergence of Extensively-Drug Resistant TB.
Dr Frontini highlighted 5 measures currently available to policy-makers to make a meaningful contribution to meeting the TB challenge:
Dr Frontini said:
“The evidence is stark. There are over 380,000 reported new cases of TB in Europe each year, and the growing problem of multi-drug resistant TB is exacerbated by people not continuing their treatment for the full six months.
World TB Day is a time to pause and reconsider the policy options. It is clear to me that hospital pharmacy has a leadership role in improving the capacity of European health systems in meeting the TB challenge. I therefore urge system designers to be mindful of the hospital pharmacy resource and work with the profession in expanding core roles such as medicines counselling, therapeutic drug monitoring and antimicrobial stewardship.
By ensuring all professions are able to maximise the contribution of their expertise, we can reverse some of the concerning trends in the area of tuberculosis.”
ENDS
For further information contact Richard Price, Policy & Advocacy Officer, richard.price@eahp.eu, +322 741 6835
NOTES TO EDITORS:
1. EAHP is an association of national organisations representing hospital pharmacists at European and international levels. More information about the EAHP and its history here.
2. World TB Day takes place on 24 March every year. It commemorates the day in 1882 when Dr Robert Koch astounded the scientific community by announcing that he had discovered the cause of tuberculosis, the TB bacillus. More information here.
3. Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at least isoniazid (INH) and rifampicin (RMP),[1] the two most powerful first-line treatment anti-TB drugs. Usually, multidrug-resistant tuberculosis can be cured with long treatments of “second-line” drugs, but these are more expensive than first-line drugs and have more adverse effects. More information here.
4. Extensively drug-resistant tuberculosis (XDR-TB) is a form of tuberculosis caused by bacteria that are resistant to some of the most effective anti-TB drugs. XDR-TB strains have arisen after the mismanagement of individuals with multidrug-resistant TB (MDR-TB). More information here.
5. Identified pharmaceutical care needs for patients with TB include support in relation to medication adherence. Whilst poor adherence to treatment is common, strategies can be put in place to improve compliance. This includes the counselling of patients by hospital pharmacists of the importance of proper use of medication to improve self-management of treatment. More information here.
6. Therapeutic Drug Monitoring is aimed at improving patient care by individually adjusting the dose of drugs for which clinical experience or clinical trials have shown improved outcome in the general or special populations. It can be based on a a priori pharmacogenetic, demographic and clinical information, and/or on the a posteriori measurement of blood concentrations of drugs (pharmacokinetic monitoring) or biological surrogate or end-point markers of effect (pharmacodynamic monitoring). Such adjustments may not be required for otherwise healthy individuals who are responding to the standard, four-drug TB regimens. However, some patients are slow to respond to treatment, have drug-resistant TB, are at risk of drug-drug interactions or have concurrent disease states that significantly complicate the clinical situation. More information here.
7. Antimicrobial stewardship refers to coordinated interventions designed to improve and measure the appropriate use of antimicrobials by promoting the selection of the optimal antimicrobial drug regimen, dose, duration of therapy, and route of administration. Evidence indicates that effective leadership from hospital pharmacist and microbiologist to champion an antimicrobial stewardship programme are two of the main elements that ensure its success. More information here and here.
8. Patients undergoing treatment for TB may often have management needs in respect of their medication during both periods in hospital and in the community. Recent research by EAHP and Europharm Forum has highlighted current deficiencies in respect of existing communication channels between healthcare professionals in hospitals and community (more information here). Potential solutions could include better utilisation of technology (e.g. shared access to the patient medical record) and learning and application from international best practice.
9. In the last thirty years only three new classes of antibiotics have been developed, with the practice of reserving new products exclusively as a treatment of last resort often cited as a limiting factor in terms of incentivising research into new products. The European Commission is seeking to assist the process of antibiotic development through the Innovative Medicines Initiative. Additional measures have also been suggested. More information here.
10) According to the World Health Organisation, a thousand new people fall victim to tuberculosis in Europe every day; over 380,000 a year. More information here.
